Matches in DBpedia 2014 for { <http://dbpedia.org/resource/JD5037> ?p ?o. }
Showing items 1 to 34 of
34
with 100 items per page.
- JD5037 abstract "JD5037 is an antiobesity drug candidate which acts as a peripherally-restricted cannabinoid inverse agonist at CB1 receptors. It is very selective for the CB1 subtype, with a Ki of 0.35nM, >700-fold higher affinity than it has for CB2 receptors.In animal studies, JD5037 does not readily cross the blood brain barrier and thus is not expected to produce the psychiatric side effects in humans which led to the withdrawal of rimonabant from the market. Its antiobesity effects are believed to be mediated by blockade of peripheral CB1 receptors, resulting in decreased leptin expression and secretion and increased leptin clearance by the kidneys. In obese mice given the drug, the resulting resensitization to leptin levels produced decreased food intake, weight loss, and normalized responses to glucose and insulin.JD5037 is covered in the following US Patents issued to Jenrin Discovery: 8,088,809 (1/3/12) ), 7,666,889 (2/23/10), 7,482,470 (1/27/09). The synthesis of JD-5037 and related analogs along with structure activity relationships has been reported.A review on the approaches and compound types being pursued as peripherally restricted CB1 receptor blockers, including JD5037, has been published.".
- JD5037 iupacName "(S)-2-((S,E)-3-(4-chlorophenyl)-N'-((4-chlorophenyl)sulfonyl)-4-phenyl-4,5-dihydro-1H-pyrazole-1-carboximidamido)-3-methylbutanamide".
- JD5037 thumbnail JD5037_skeletal.png?width=300.
- JD5037 wikiPageID "36562173".
- JD5037 wikiPageRevisionID "606333792".
- JD5037 c "27".
- JD5037 chemspiderid "28663876".
- JD5037 cl "2".
- JD5037 drugName "JD5037".
- JD5037 h "27".
- JD5037 hasPhotoCollection JD5037.
- JD5037 inchi "1".
- JD5037 inchikey "GTCSIQFTNPTSLO-RPWUZVMVBY".
- JD5037 iupacName "-2".
- JD5037 molecularWeight "572.506".
- JD5037 n "5".
- JD5037 o "3".
- JD5037 s "1".
- JD5037 smiles "CC[C@@H]N/C/N2C[C@@H]C4=CC=CC=C4".
- JD5037 stdinchi "1".
- JD5037 stdinchikey "GTCSIQFTNPTSLO-RPWUZVMVSA-N".
- JD5037 subject Category:Cannabinoids.
- JD5037 subject Category:Drugs_acting_on_the_nervous_system.
- JD5037 type Drug.
- JD5037 type FunctionalSubstance.
- JD5037 comment "JD5037 is an antiobesity drug candidate which acts as a peripherally-restricted cannabinoid inverse agonist at CB1 receptors. It is very selective for the CB1 subtype, with a Ki of 0.35nM, >700-fold higher affinity than it has for CB2 receptors.In animal studies, JD5037 does not readily cross the blood brain barrier and thus is not expected to produce the psychiatric side effects in humans which led to the withdrawal of rimonabant from the market.".
- JD5037 label "JD5037".
- JD5037 sameAs m.0kfxzb0.
- JD5037 sameAs Q6107933.
- JD5037 sameAs Q6107933.
- JD5037 wasDerivedFrom JD5037?oldid=606333792.
- JD5037 depiction JD5037_skeletal.png.
- JD5037 isPrimaryTopicOf JD5037.
- JD5037 name "JD5037".
